טוען...
Prolonged First-Dose Hypotension Induced by Sacubitril/Valsartan
Entresto was recommanded by major guidelines as the frontline therapy for heart failure with reduced ejection fraction since its clinical benefit was proved by the PARADIGM-HF trial. Angiotensin converting enzyme inhibitors are the cornerstone of the treatment of HF. Varying incidences of first-dose...
שמור ב:
| הוצא לאור ב: | Acta Cardiol Sin |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taiwan Society of Cardiology
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5777949/ https://ncbi.nlm.nih.gov/pubmed/29375230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6515/ACS.201801_34(1).20170614A |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|